These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37868796)

  • 21. Optical coherence tomography angiography biomarkers in a bi-monthly maintenance dosing aflibercept in patients with neovascular age-related macular degeneration.
    Park JB; Kim K; Kang MS; Kim ES; Yu SY
    BMC Ophthalmol; 2023 Jul; 23(1):314. PubMed ID: 37438681
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Central Retinal Vein Occlusion.
    Sen P; Gurudas S; Ramu J; Patrao N; Chandra S; Rasheed R; Nicholson L; Peto T; Sivaprasad S; Hykin P
    Ophthalmol Retina; 2021 Nov; 5(11):1115-1124. PubMed ID: 33610836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Macular thickness fluctuation in neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor.
    Chen ER; Chen AX; Greenlee TE; Conti TF; Briskin IN; Urbano CA; Kalur A; Kaiser PK; Singh RP
    Can J Ophthalmol; 2022 Oct; 57(5):350-356. PubMed ID: 34283969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Faricimab in neovascular AMD: first report of real-world outcomes in an independent retina clinic.
    Stanga PE; Valentín-Bravo FJ; Stanga SEF; Reinstein UI; Pastor-Idoate S; Downes SM
    Eye (Lond); 2023 Oct; 37(15):3282-3289. PubMed ID: 36959312
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-World Weekly Efficacy Analysis of Faricimab in Patients with Age-Related Macular Degeneration.
    Muth DR; Fasler KF; Kvanta A; Rejdak M; Blaser F; Zweifel SA
    Bioengineering (Basel); 2024 May; 11(5):. PubMed ID: 38790345
    [No Abstract]   [Full Text] [Related]  

  • 26. Short-term outcomes of intravitreal faricimab for treatment-naïve neovascular age-related macular degeneration.
    Matsumoto H; Hoshino J; Nakamura K; Nagashima T; Akiyama H
    Graefes Arch Clin Exp Ophthalmol; 2023 Oct; 261(10):2945-2952. PubMed ID: 37195339
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial.
    Sahni J; Patel SS; Dugel PU; Khanani AM; Jhaveri CD; Wykoff CC; Hershberger VS; Pauly-Evers M; Sadikhov S; Szczesny P; Schwab D; Nogoceke E; Osborne A; Weikert R; Fauser S
    Ophthalmology; 2019 Aug; 126(8):1155-1170. PubMed ID: 30905643
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Anti-Vascular Endothelial Growth Factor Agents.
    Evans RN; Reeves BC; Maguire MG; Martin DF; Muldrew A; Peto T; Rogers C; Chakravarthy U
    JAMA Ophthalmol; 2020 Oct; 138(10):1043-1051. PubMed ID: 32816002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Macular neovascularization lesion type and vision outcomes in neovascular age-related macular degeneration: post hoc analysis of HARBOR.
    Freund KB; Staurenghi G; Jung JJ; Zweifel SA; Cozzi M; Hill L; Blotner S; Tsuboi M; Gune S
    Graefes Arch Clin Exp Ophthalmol; 2022 Aug; 260(8):2437-2447. PubMed ID: 35239009
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial.
    Mori R; Honda S; Gomi F; Tsujikawa A; Koizumi H; Ochi H; Ohsawa S; Okada AA;
    Jpn J Ophthalmol; 2023 May; 67(3):301-310. PubMed ID: 37039948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Macular Telangiectasia Type 2: A Classification System Using MultiModal Imaging MacTel Project Report Number 10.
    Chew EY; Peto T; Clemons TE; Sallo FB; Pauleikhoff D; Leung I; Jaffe GJ; Heeren TFC; Egan CA; Charbel Issa P; Balaskas K; Holz FG; Gaudric A; Bird AC; Friedlander M
    Ophthalmol Sci; 2023 Jun; 3(2):100261. PubMed ID: 36846105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. YOSEMITE and RHINE: Phase 3 Randomized Clinical Trials of Faricimab for Diabetic Macular Edema: Study Design and Rationale.
    Eter N; Singh RP; Abreu F; Asik K; Basu K; Baumal C; Chang A; Csaky KG; Haskova Z; Lin H; Ruiz CQ; Ruamviboonsuk P; Silverman D; Wykoff CC; Willis JR
    Ophthalmol Sci; 2022 Mar; 2(1):100111. PubMed ID: 36246184
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictive effect of TCED-HFV grading and imaging biomarkers on anti-VEGF therapy in diabetic macular edema.
    Yu L; Hao X; Cheng J; Ling Y; Ren H; Mo B; Liu W
    BMC Ophthalmol; 2023 May; 23(1):232. PubMed ID: 37221461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation of 3-Dimensionally Quantified Intraretinal and Subretinal Fluid With Visual Acuity in Neovascular Age-Related Macular Degeneration.
    Waldstein SM; Philip AM; Leitner R; Simader C; Langs G; Gerendas BS; Schmidt-Erfurth U
    JAMA Ophthalmol; 2016 Feb; 134(2):182-90. PubMed ID: 26661463
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration.
    Jackson TL; Slakter J; Buyse M; Wang K; Dugel PU; Wykoff CC; Boyer DS; Gerometta M; Baldwin ME; Price CF;
    Ophthalmology; 2023 Jun; 130(6):588-597. PubMed ID: 36754174
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Accuracy of a Machine-Learning Algorithm for Detecting and Classifying Choroidal Neovascularization on Spectral-Domain Optical Coherence Tomography.
    Maunz A; Benmansour F; Li Y; Albrecht T; Zhang YP; Arcadu F; Zheng Y; Madhusudhan S; Sahni J
    J Pers Med; 2021 Jun; 11(6):. PubMed ID: 34201045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Faricimab Effectively Resolves Intraretinal Fluid and Preserves Vision in Refractory, Recalcitrant, and Nonresponsive Neovascular Age-Related Macular Degeneration.
    Cheng AM; Joshi S; Banoub RG; Saddemi J; Chalam KV
    Cureus; 2023 Jun; 15(6):e40100. PubMed ID: 37425528
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy, durability, and safety of faricimab in patients from Asian countries with neovascular age-related macular degeneration: 1-Year subgroup analysis of the TENAYA and LUCERNE trials.
    Takahashi K; Cheung CMG; Iida T; Lai TYY; Ohji M; Yanagi Y; Kawano M; Ohsawa S; Suzuki T; Kotecha A; Lin H; Patel V; Swaminathan B; Lee WK;
    Graefes Arch Clin Exp Ophthalmol; 2023 Nov; 261(11):3125-3137. PubMed ID: 37294433
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Automatic prediction of treatment outcomes in patients with diabetic macular edema using ensemble machine learning.
    Liu B; Zhang B; Hu Y; Cao D; Yang D; Wu Q; Hu Y; Yang J; Peng Q; Huang M; Zhong P; Dong X; Feng S; Li T; Lin H; Cai H; Yang X; Yu H
    Ann Transl Med; 2021 Jan; 9(1):43. PubMed ID: 33553336
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration?
    Patel Y; Miller DM; Fung AE; Hill LF; Rosenfeld PJ
    Ophthalmol Retina; 2020 Feb; 4(2):141-147. PubMed ID: 31735634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.